POH 0.00% 0.0¢ progress 2023-2 trust

Terumo and Propofol Injectable, page-118

  1. 3,464 Posts.
    lightbulb Created with Sketch. 2300
    USPTO has published Phosphagenics’ application for a Pharmaceutical Formulation patent which is intended to protect the use of TPM in a broad range of injectable formulations (Pub. No: 20190015329, Pub. Date: 17/01/19). This patent, along with a joint Phosphagenics-Terumo patent specifically for TPM/Propofol, was referred to by the company in a November 2017 update.

    The TPM formulation is described as suitable for topical, enteral or parenteral administration, but is considered particularly suitable as an injectable formulation.

    https://www.uspto.gov/
 
watchlist Created with Sketch. Add POH (ASX) to my watchlist
(20min delay)
Last
0.0¢
Change
0.000(0.00%)
Mkt cap ! n/a
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
POH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.